Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN7075 + cemiplimab + bevacizumab + trifluridine + tipiracil
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a **combination regimen** consisting of five agents: REGN7075 (a costimulatory bispecific antibody targeting EGFR and CD28 to restore immune sensitivity and activate T cells), cemiplimab (a PD-1 immune checkpoint inhibitor), bevacizumab (a monoclonal antibody against VEGF, inhibiting angiogenesis), and trifluridine plus tipiracil (a nucleoside analogue antimetabolite and a thymidine phosphorylase inhibitor, used as a cytotoxic chemotherapy). The combination is under investigation for the treatment of advanced/metastatic solid tumors, especially metastatic colorectal cancer (mCRC), refractory to standard therapies[1][3][5][6][10].
- Brand names
- Lonsurf
- Other names
- trifluridine/tipiracilREGN7075REGN-7075REGN 7075cemiplimabbevacizumab
02
Targets
CD28 (Cluster of Differentiation 28)DNAEGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TYMP (Thymidine phosphorylase)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on REGN7075 + cemiplimab + bevacizumab + trifluridine + tipiracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN7075 + cemiplimab + bevacizumab + trifluridine + tipiracil.